Zydus Completes €256 Million Acquisition of 85.6% Stake in Amplitude Surgical, to Launch Tender Offer

Zydus Lifesciences Ltd has officially completed the acquisition of an 85.6% stake in France-based orthopaedic company Amplitude Surgical. The deal was finalised on July 29, 2025, after all required conditions were met. The acquisition was carried out at €6.25 per share, amounting to a total deal value of €256 million.

CEO Retained and Continued Investment

Olivier Jallabert will continue to serve as the CEO of Amplitude Surgical. As part of the acquisition, he has also reinvested in the company. Following the transaction, Amplitude terminated its existing liquidity agreement dated June 19, 2018, with Oddo BHF and Natixis.

Next Step: Tender Offer for Remaining Shares

Zydus plans to file a simplified mandatory tender offer on July 30, 2025, to acquire the remaining outstanding shares at the same price of €6.25 per share. With binding commitments from shareholders holding 4.7% of Amplitude's shares, Zydus is expected to reach over 90% ownership and proceed with a squeeze-out of the remaining shareholders. Subject to clearance from the French financial regulator (AMF), the offer is likely to begin in September 2025.

Board Support and Fairness Opinion

Amplitude Surgical’s Board of Directors has unanimously welcomed the offer. On July 28, the Board shared a favourable opinion after receiving a fairness assessment from Finexsi, appointed as an independent expert.

About Zydus Lifesciences

Zydus Lifesciences Ltd is a global pharmaceutical company committed to developing and marketing a wide range of healthcare products. With over 27,000 employees, including 1,400 scientists, Zydus focuses on making impactful healthcare solutions accessible and affordable worldwide.

Also Read: Coforge Announces Completion of 100% Acquisition of TMLabs Pty Ltd!

Zydus Lifesciences Share Price Movement

As of July 29, 2025, Zydus Lifesciences share price (NSE: ZYDUSLIFE) is trading at ₹995.60 per share, reflecting a gain of ₹15.50 or 1.58% for the day. The stock opened at ₹985.00, reached a high of ₹997.95, and a low of ₹980.55 during the trading session. The company’s market capitalisation stands at ₹1.00 lakh crore. It has a price-to-earnings (P/E) ratio of 22.14 and offers a dividend yield of 1.10%. The stock has a 52-week high of ₹1,324.30 and a 52-week low of ₹795.00. The quarterly dividend amount is ₹2.74 per share.

Conclusion

 The acquisition of Amplitude Surgical strengthens Zydus's global footprint in the medical devices space. With the upcoming tender offer and the potential for full ownership, Zydus aims to accelerate its expansion in the orthopaedic solutions market, further aligning with its mission to transform lives through innovation in healthcare.

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions.

Investments in the securities market are subject to market risks, read all the related documents carefully before investing.